BioNxt Solutions Inc. Stock price

Equities

BNXT

CA0909741062

Pharmaceuticals

Delayed Canadian Securities Exchange 03:13:23 2024-03-28 pm EDT 5-day change 1st Jan Change
0.47 CAD 0.00% Intraday chart for BioNxt Solutions Inc. -2.08% -3.09%
Sales 2021 0.29 0.39 Sales 2022 0.3 0.4 Capitalization 53.81M 72.89M
Net income 2021 -20M -27.09M Net income 2022 -12M -16.25M EV / Sales 2021 292,725,534 x
Net Debt 2021 4.1 5.56 Net Debt 2022 4.23 5.74 EV / Sales 2022 180,922,093 x
P/E ratio 2021
-3.68 x
P/E ratio 2022
-3.99 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 93.08%
More Fundamentals * Assessed data
Dynamic Chart
1 week-2.08%
Current month-24.19%
1 month-21.67%
3 months-3.09%
6 months+40.30%
Current year-3.09%
More quotes
1 week
0.46
Extreme 0.46
0.53
1 month
0.46
Extreme 0.46
0.63
Current year
0.46
Extreme 0.46
0.75
1 year
0.25
Extreme 0.25
0.75
3 years
0.25
Extreme 0.25
2.95
5 years
0.25
Extreme 0.25
3.55
10 years
0.25
Extreme 0.25
3.55
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 17-12-11
Director of Finance/CFO 39 21-11-18
Director/Board Member 43 18-12-11
Members of the board TitleAgeSince
Director of Finance/CFO 39 21-11-18
Chief Executive Officer 44 17-12-11
Director/Board Member 58 18-12-09
More insiders
Date Price Change Volume
24-03-28 0.47 -6.00% 8,500
24-03-27 0.5 +8.70% 35,150
24-03-26 0.46 -4.17% 19,450
24-03-21 0.48 -1.03% 10,500
24-03-20 0.485 -10.19% 11,100

Delayed Quote Canadian Securities Exchange, March 28, 2024 at 03:13 pm EDT

More quotes
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany. The Company is also focused on regulatory approval and commercialization of medical products for European markets. The Company, through its subsidiary, 3a-diagnostics GmbH, offers diagnostic products, which include COVID-19 PCR Diagnostic Kit and Peri-Implantitis Oral Biosensor.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock BioNxt Solutions Inc. - Canadian Securities Exchange